Climb Bio (NASDAQ:CLYM) used an investor R&D spotlight event to outline its strategy around CD19-targeted B-cell depletion ...

Robust B-cell depletion observed with budoprutug subcutaneous formulation in healthy volunteers, supporting continued developmentBudoprutug pMN, ...

UCB has agreed to acquire Candid Therapeutics for up-to-$2.2 billion, in a deal designed to expand the buyer’s presence in ...

Development and Readiness Pilot (CDRP) program supports the acceleration of manufacturing readiness for therapies with ...

Early GO decision reached in CAPTIVATE in March 2026 based on GO criteria of 20 confirmed responders achieved with less than 40 planned ...

After failing to muster sufficient support for an IPO last year, autoimmune and inflammatory disease specialist Odyssey ...

UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager ...

ZYNLONTA combo trials in r/r DLBCL, key LOTIS-5 data Q2 2026, strong ORR/CR, cash to 2028—read now. Click for this ADCT ...

Global Immune Repertoire Sequencing Market OverviewThe global immune repertoire sequencing market is projected to expand at a steady compound annual growth rate of approximately 10% during the ...

Belgian biotech UCB has made its second acquisition of the year, agreeing a front-loaded takeover of US biotech Candid ...

UCB to buy clinical-stage biotech company, Candid Therapeuticsfor US$ 2.2 billion: Brussels, Belgium Tuesday, May 5, 2026, 09:00 Hrs [IST] UCB, a global biopharmaceutical company, ...

UCB, a global biopharmaceutical company, today announced signing of a definitive agreement under which it would acquire Candid Therapeutics (Candid), a privately held clinical-stage biotechnology ...